– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(Nasdaq: IONS ) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts . New data at ACAAI demonstrate donidalorsen significantly reduced HAE attacks, translating to high levels of disease control and significant and clinically meaningful improvements in quality-of-life across multiple measures in a vast majority of patients, sustained up to three years.
Presentations include: Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema: A Week 197 Analysis e-Poster Presentation: October 25, 2024 (Monitor 21, Exhibit Hall A) Presenting Author: Michael Manning Impact of Donidalorsen on Patient-Reported Outcomes: Results from the Phase 3 OASIS-HAE Study e-Poster Presentation: October 25, 2024 (Monitor 21, Exhibit Hall A) Presenting Author: Aaron Yarlas Treatment Of Hereditary Angioedema: Safety, Efficacy, and Patient Pr.
